Compare Motorola Solutions Inc (MSI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Novo Nordisk A/S — how do they compare? Motorola Solutions Inc trades at $448.15 (market cap $74.00B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.2× Motorola Solutions Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Novo Nordisk A/S for 116 Days on average.
| MSI | NVO | |
|---|---|---|
Market Cap | $74.00B | $165.31B |
Volume | 722,147 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $491.24 | $63.98 |
52-Week Low | $363.83 | $35.29 |
Typical Hold Time | 100 Days | 116 Days |
Enterprise Value | $82.90B | $179.56B |
Dividend Yield | 1.08% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and a record $15.6B backlog. Recent acquisitions like D-Fend Solutions and a $139M Louisiana public safety contract highlight expansion in security and AI-driven solutions. Earnings have consistently beaten estimates, with Q2 2026 EPS of $4.41 surpassing the $3.85 expectation. However, cash flow trends show significant investing outflows for growth initiatives.
The outlook remains positive given analyst consensus with a $525.86 price target and 70.59% buy ratings, though risks include high valuation multiples and increased debt levels from acquisitions. The stock's current bearish technical stance may present a buying opportunity if fundamentals continue to strengthen, but investors should monitor cash flow sustainability and integration of recent purchases.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
